Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

11 questions · 11 findings · 6 reviews

No studies found 2 · 18.2%GRADE not reported 2 · 18.2%Very low 0 · 0%Low 2 · 18.2%Moderate 3 · 27.3%High 2 · 18.2%

DOAC vs placebo

Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).

1 finding from 1 review

DOAC vs heparin

Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (high certainty).

1 finding from 1 review

DOAC vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding‐ clinically relevant non‐major Treatment duration 28 ‐ 42… compared with placebo (moderate certainty).

1 finding from 1 review

DOAC vs heparin

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ clinically relevant, non‐major Treatment duration 28 ‐ 42… compared with heparin (high certainty).

1 finding from 1 review

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs standard local care

Major bleeding, requiring transfusion of packed red blood cells · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in major bleeding requiring transfusion of packed red blood cells compared with standard care (usual local haemostatic measures: gelatin sponge and…; GRADE not reported.

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Major bleeding, requiring transfusion of packed red blood cells · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in major bleeding requiring transfusion of packed red blood cells compared with placebo (placebo solution/mouthwash); GRADE not reported.

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Bleeding duration (minutes, all types of bleeding, minor and major) · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…

The review found no eligible studies for this question.

1 finding from 1 review